Asterias Biotherapeutics Ownership
Asterias Biotherapeutics holds a total of 55.66 Million outstanding shares. Asterias Biotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Asterias Biotherapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Asterias Biotherapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Asterias |
Asterias Stock Ownership Analysis
About 40.0% of the company shares are held by company insiders. The book value of Asterias Biotherapeutics was presently reported as 1.16. The company recorded a loss per share of 0.37. Asterias Biotherapeutics had not issued any dividends in recent years. The entity had 1348:1000 split on the 2nd of October 2014. Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 31 people. For more info on Asterias Biotherapeutics please contact the company at 510 456-3800 or go to www.asteriasbiotherapeutics.com..Asterias Biotherapeutics Outstanding Bonds
Asterias Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Asterias Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Asterias bonds can be classified according to their maturity, which is the date when Asterias Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Assurant 7 percent Corp BondUS04621XAK46 | View | |
| ASSURANT INC 49 Corp BondUS04621XAJ72 | View | |
| ASSURANT INC 675 Corp BondUS04621XAD03 | View | |
| US04621XAM02 Corp BondUS04621XAM02 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| AIZ 265 15 JAN 32 Corp BondUS04621XAN84 | View |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Asterias Stock
If you are still planning to invest in Asterias Biotherapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Asterias Biotherapeutics' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |